June 10, 2010
Officials at Texas Tech University System's Office of Technology Commercialization announced Wednesday (June 9) the signing of an exclusive worldwide license agreement for a chemical additive called an aptamer that makes certain existing antibiotics viable against antibiotic-resistant bacteria.
The agreement is with RI Scientific LLC for the development and commercialization of metallo-beta-lactamase inhibitors, short chains of nucleic acid that have demonstrated the ability to eliminate bacterial resistance to antibiotics.
"This technology is extremely important in terms of the number of people who can benefit from it," said David L. Miller, vice chancellor for commercialization. "We believe that RI Scientific has the ability to work with a number of pharmaceutical companies through the clinical testing process to have the aptamers incorporated into many of the commonly used antibiotics that the medical community now depends on."